Karyopharm Therapeutics | KPTI - الأصول





الأصول تغيير تاريخ
AbbVie USD 133.96B 62M 2025-12
Abbott USD 110.43B 23.72B 2026-03
Amgen USD 92.5B 1.92B 2026-03
AstraZeneca USD 114.02B 59M 2026-03
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Incyte USD 7.34B 381.14M 2026-03
J&J USD 200.89B 1.68B 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
MacroGenics USD 256.85M 13.92M 2025-12
Merck USD 128.68B 8.18B 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Novartis USD 118.53B 7.58B 2026-03
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 207.62B 542M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Takeda JPY 15.41T 938.47B 2025-12
Tectonic Therapeutic USD 261.04M 15.96M 2025-12
TG Therapeutics USD 1.06B 38.23M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Xencor USD 875.5M 6.68M 2025-12